April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Exploratory Study of Nepafenac as Adjunctive Therapy for Diabetic Macular Edema
Author Affiliations & Notes
  • Josh O. Wallsh
    Ophthalmology, Retina Macula Institute, Torrance, California
  • Mehran Taban
    Ophthalmology, Retina Macula Institute, Torrance, California
  • Ben Sharareh
    Ophthalmology, Retina Macula Institute, Torrance, California
  • Elijah Moon
    Ophthalmology, Retina Macula Institute, Torrance, California
  • Ron P. Gallemore
    Ophthalmology, Retina Macula Institute, Torrance, California
  • Footnotes
    Commercial Relationships  Josh O. Wallsh, None; Mehran Taban, None; Ben Sharareh, None; Elijah Moon, None; Ron P. Gallemore, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 560. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Josh O. Wallsh, Mehran Taban, Ben Sharareh, Elijah Moon, Ron P. Gallemore; Exploratory Study of Nepafenac as Adjunctive Therapy for Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2011;52(14):560.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To test the efficacy of the topical non-steroidal anti-inflammatory drop, nepafenac, in the management of diabetic macular edema (DME).

Methods: : A randomized, double-masked, exploratory study of topical nepafenac 0.1% versus placebo as adjuntive therapy for DME undergoing standard of care treatment with focal laser using endpoints of central macular thickness, visual acuity, and number of focal laser treatments. High-resolution OCT was used to measure macular thickness (Cirrus, Zeiss Ophthalmics). A vehicle drop was used as the control. In addition, Argon focal laser was applied when indicated at baseline and thereafter as indicated using ETDRS criteria.

Results: : At 8 months, visual acuity decreased an average of 4.67±13.17 ETDRS letters and central macular thickness increased an average of 27.33±66.81 microns in the control group (n = 6) versus an increase of 1.14±6.85 ETDRS letters and a decrease of 17.58±33.46 microns in the treatment group (n = 7). The mean number of focal laser treatments was 53.44±34.67 applications for the control group (n = 9) versus 44.43±30.77 applications for the treatment group (n = 10).

Conclusions: : Nepafenac reduced macular thickness, improved visual acuity, and reduced the number of laser applications compared to the control group for patients with DME. A larger study with increased power is warranted.

Clinical Trial: : http://www.clinicaltrials.gov NCT00939276

Keywords: diabetic retinopathy • macula/fovea • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×